Safety of Tinted Soft Scleral Eye Shields When IPL is Applied on Eyelids
Safety of Tinted Soft Scleral Eye Shields When IPL is Applied Directly on Eyelids of Subjects With Dry Eye Disease Due to Meibomian Gland Dysfunction
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37215
- Toyos Clinic
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject is able to read, understand and sign an IC form
- 22 or older
- Self-assessed symptoms are consistent with dry eye (SPEED score ≥ 10)
- Signs of MGD, as detected in biomicroscopy
- Fitzpatrick skin type I-V
- Subject is willing to comply with all study procedures, including return to the clinic 1 day and 1 week after the first and only treatment within the scope of the study
Exclusion Criteria:
• Fitzpatrick skin type VI
- Ocular surgery or eyelid surgery, within 3 months prior to screening
- Recent ocular trauma, within 3 months prior to screening
- Pre-cancerous lesions, skin cancer or pigmented lesions in the planned treatment area
- Severe active allergies, or other severe uncontrolled eye disorders affecting the ocular surface
- Uncontrolled infections or uncontrolled immunosuppressive diseases
- Subjects with ocular infections requiring the use of antibiotic treatment, within 3 months prior to screening
- Legally blind in either eye
- Ocular surface abnormality that may compromise corneal integrity in either eye (e.g., keratoconus, recurrent corneal erosion, corneal epithelial defect, Grade 3 corneal fluorescein staining, map dot fingerprint dystrophy, prior chemical burn)
- Eyelid abnormalities that affect lid function in either eye, including: entropion, ectropion, tumor, blepharospasm, lagophthalmos, severe trichiasis, and severe ptosis
- Prior history of cold sores or rashes in the perioral area or in the planned treatment area that could be stimulated by light at a wavelength of 560 nm to 1200 nm, including: Herpes simplex 1 & 2, Systemic Lupus erythematosus, and porphyria
- Within 3 months prior to screening, use of photosensitive medication and/or herbs that may cause sensitivity to 560-1200 nm light exposure, including: Isotretinoin, Tetracycline, Doxycycline, and St. John's Wort
- Over exposure to sun, within 4 weeks prior to screening
- Moderate to severely compromised corneal health as assessed by corneal fluorescein staining
- Trans-illumination defects
- Anisocoria or pupil deformation
- Anterior chamber inflammation
- Media opacities (cataract, posterior capsule opacification, corneal edema, etc.) that preclude clear visualization of the anterior segment and retina
- Any condition revealed whereby the investigator deems the subject inappropriate for this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Study arm
Protection of eyes with tinted soft scleral eye shields followed by IPL administration directly on eyelids
|
In subjects with dry eye disease due to meibomian gland dysfunction, protection of eyes with tinted soft scleral eye shields followed by IPL administration on eyelids
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ophthalmic morphological changes at 1 week after intervention
Time Frame: 1 week
|
Opinion of the study investigator (yes/no) whether there was any change in ocular structures at 1 week after intervention (based on a series of tests including biomicroscopy, corneal fluorescein staining, anterior segment OCT, posterior segment OCT, and specular microscopy)
|
1 week
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ophthalmic morphological changes at 10 minutes after intervention
Time Frame: 10 minutes
|
Opinion of the study investigator (yes/no) whether there was any change in ocular structures at 10 minutes after intervention (based on a series of tests including biomicroscopy, corneal fluorescein staining, anterior segment OCT, posterior segment OCT, and specular microscopy)
|
10 minutes
|
|
Ophthalmic morphological changes at 24 hours after intervention
Time Frame: 24 hours
|
Opinion of the study investigator (yes/no) whether there was any change in ocular structures at 24 hours after intervention (based on a series of tests including biomicroscopy, corneal fluorescein staining, anterior segment OCT, posterior segment OCT, and specular microscopy)
|
24 hours
|
|
Objective functional change at 10 minutes after intervention
Time Frame: 10 minutes
|
Change in best-corrected visual acuity (ETDRS chart) at 10 minutes after intervention
|
10 minutes
|
|
Objective functional change at 24 hours after intervention
Time Frame: 24 hours
|
Change in best-corrected visual acuity (ETDRS chart) at 24 hours after intervention
|
24 hours
|
|
Objective functional change at 1 week after intervention
Time Frame: 1 week
|
Change in best-corrected visual acuity (ETDRS chart) at 1 week after intervention
|
1 week
|
|
Subjective functional change at 10 minutes after intervention
Time Frame: 10 minutes
|
Change in perception of visual symptoms (Visual analog scale) at 10 minutes after intervention
|
10 minutes
|
|
Subjective functional change at 1 day after intervention
Time Frame: 1 day
|
Change in perception of visual symptoms (Visual analog scale) at 1 day after intervention |
1 day
|
|
Subjective functional change at 1 week after intervention
Time Frame: 1 week
|
Change in perception of visual symptoms (Visual analog scale) at 1 week after intervention |
1 week
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Rolando Toyos, MD, Toyos Clinic (Nashville, TN, USA)
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- LUM-VBU-OPT-21-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.